+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
PDPL

Parenteral Drugs (India) Share Price

₹2.90 +0 (0%)

21 Aug, 2023 1:45 PM (IST)

Parenteral Drugs (India) live price: ₹2.90. It opened at ₹3 vs previous close ₹3; intraday high/low: ₹3/₹3. The 50 & 200 DMA stand at ₹3.50/₹3.70.

Parenteral Drugs (India) Performance

  • Today's Low
  • ₹3
  • Today's High
  • ₹3
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹3
  • Previous Close₹3
  • Volume2,313
  • 50 DMA₹3.50
  • 100 DMA₹3.50
  • 200 DMA₹3.70

Parenteral Drugs (India) Chart

Investment Returns

Smart Investing Starts Here Start SIP with Parenteral Drugs (India) for Steady Growth!

Invest Now

Parenteral Drugs (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -0.1
  • PEG Ratio
  • -0
  • Market Cap Cr
  • 9
  • P/B Ratio
  • -0
  • Average True Range
  • 0.2
  • EPS
  • -25.6
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.2
  • RSI
  • 36.04
  • MFI
  • 3.73

Latest Stock News Updates

Sai Parenteral's makes positive debut; shares list at 3% premium on BSE

The positive listing of Sai Parenteral's shares defied the grey market trend, in which the counter traded almost flat.

SAI Parenteral's buys 74.6% stake in Australia's Noumed Pharmaceuticals for 125 crore

Noumed Pharmaceuticals is a supplier of private label over the counter products to pharmacy chains across Australia and New Zealand

PARENTERAL DRUGS (INDIA) LTD.-$ - 524689 - Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal

According to Regulation 30 of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) and in accordance with the requirements of Sub clause 16(k) of Para A of part A of Schedule III of Listing Regulations, we wish to inform you that the Hon''ble NCLT, Mumbai has approved the resolution plan in the matter of the Corporate Debtor namely Parenteral Drugs(India) Ltd. vide their order dated 16.01.2025 as enclosed hereunder

Parenteral Drugs (India) Financials

Parenteral Drugs (India) Technicals

EMA & SMA

Current Price
₹2.90
0 (0%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹3.20
  • 50 Day
  • ₹3.50
  • 100 Day
  • ₹3.50
  • 200 Day
  • ₹3.70

Resistance and Support

2.83 Pivot Speed
  • R3 3.20
  • R2 3.00
  • R1 3.00
  • S1 2.80
  • S2 2.60
  • S3 2.60

Parenteral Drugs (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2022-05-30 Audited Results & Others Inter alia, to consider : The shifting of registered office of the Company within local limits of the city.
2022-02-14 Quarterly Results
2022-02-02 Others inter alia, To consider appointment of Independent Director and to consider sale, lease or disposal of the whole or substantially the whole of the undertaking of the Company.
2021-11-12 Quarterly Results
2021-08-10 Quarterly Results

Parenteral Drugs (India) Shareholding Pattern

73.29%
26.7%
0.01%
0%

About Parenteral Drugs (India)

Parenteral Drugs (India) Company engaged primarily in the business of Manufacturing of Pharmaceutical Product. The Company is also engaged in trading in various products. View More
  • NSE Symbol
  • PDPL
  • BSE Symbol
  • 524689
  • Executive Director,Managing Director,Chief Financial Officer
  • Vinod Kumar Gupta
  • ISIN
  • INE904D01019

Similar Stocks to Parenteral Drugs (India)

Parenteral Drugs (India) FAQs

Parenteral Drugs (India) share price is ₹2 As on 20 August, 2026 | 07:51

The Market Cap of Parenteral Drugs (India) is ₹8.6 Cr As on 20 August, 2026 | 07:51

The P/E ratio of Parenteral Drugs (India) is -0.1 As on 20 August, 2026 | 07:51

The PB ratio of Parenteral Drugs (India) is -0 As on 20 August, 2026 | 07:51

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23